Table 5. DHX32 and RGS12 association with clinical response in anti-CCP positive RA patients according to anti-TNF therapy.

				All anti-TNF		Infliximab		Adalimumab		Etanercept
SNP (gene)	Minor Allele	Major Allele	MAF	OR(95%CI)	P	OR(95%CI)	P	OR(95%CI)	P	OR(95%CI)	P
rs12356233 (DHX32)	G	A	0.39	1.09(0.73–1.64)	0.66	0.85(0.42–1.7)	0.64	2.65(1.25–5.6)	0.0095*	0.7(0.35–1.42)	0.32
rs2857859 (RGS12)	T	C	0.29	0.64(0.4–1.03)	0.062	0.4(0.17–0.99)	0.042	1.01(0.45–2.25)	0.99	0.68(0.31–1.48)	0.33
rs4690093 (RGS12)	G	A	0.3	0.85(0.55–1.32)	0.46	1.13(0.57–2.24)	0.73	0.4(0.16–0.99)	0.049	1.06(0.48–2.31)	0.89

MAF: minor allele frequency in all anti-CCP RA patients; OR: odds ratio; CI: odds ratio confidence interval; P: nominal significance in association test with clinical response at week 12.

*significant (P<0.05) after multiple test correction.